Global Hemophilia Market: Industry Analysis & Outlook (2018-2022)

  • ID: 4471580
  • Report
  • Region: Global
  • 90 Pages
  • Koncept Analytics
1 of 5
Progressing Drug Pipeline to Support Hemophilia Market

FEATURED COMPANIES

  • Bayer Group
  • Novo Nordisk
  • Pfizer Inc.
  • Shire PLC
  • MORE

The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion of the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes abnormal bleeding with poor clotting. It is classified into hemophilia A, hemophilia B, hemophilia C, and hemophilia with inhibitors.

Treatment for hemophilia is done via replacement therapy, prophylactic therapy, on-demand therapy, gene therapy and many others. Gene therapy is being regarded as an attractive option for treatment of hemophilia. By the year 2030, the pharmaceutical companies are expected to launch their gene therapy treatment for hemophilia, and this might affect the market dynamics at large.

The growth factors of the hemophilia market include increased focus on prophylactic treatment, growing market for FVIII, increasing diagnosis rate, and increasing healthcare expenditure. Major trends of the market include development of novel hemophilia treatment, shifting to extended half-life therapies and growing popularity of gene therapy. Further, growth prospects are hindered by high cost of therapy and consumer’s reluctance in switching to new therapy options.

The report offers an in-depth analysis of the global hemophilia market. It covers the global as well as regional aspect of the market. The top notch players in the market exhibit a very close competitive landscape. The report profiles Pfizer Inc., Bayer Group, Shire PLC, and Novo Nordisk.

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer Group
  • Novo Nordisk
  • Pfizer Inc.
  • Shire PLC
  • MORE

1. Market Overview
1.1 Hemophilia
1.2 Types of Hemophilia
1.3 Signs & Symptoms
1.4 Diagnosis & Treatment

2. Global Market Analysis
2.1 Global Hemophilia Market by Value
2.2 Global Hemophilia Market Forecast by Value
2.3 Global Hemophilia Market by Treatment Regimen
2.4 Global Hemophilia Market by Type
2.4.1 Global Hemophilia A Market Forecast by Value
2.4.2 Global Hemophilia A Market by Severity
2.4.3 Global Hemophilia A Market by Treatment Regimen
2.4.4 Global Hemophilia with Inhibitors Market Forecast by Value
2.4.5 Global Hemophilia B Market Forecast by Value
2.4.6 Global Hemophilia B Market by Severity
2.4.7 Global Hemophilia B Market by Treatment Regimen

3. Regional Market Analysis
3.1 The US
3.1.1 The US Hemophilia Market by Value
3.1.2 The US Hemophilia Market Forecast by Value
3.1.3 The US Hemophilia Market by Type
3.1.4 The US Hemophilia A Market Forecast by Value
3.1.5 The US Hemophilia A Market by Products
3.1.6 The US Hemophilia A Market-Treated Patient Volume Forecast
3.1.7 The US Hemophilia A Market-Severe Patients on Prophylactic Therapy
3.1.8 The US Hemophilia A Market-Severe Patients on On-Demand Therapy
3.1.9 The US Hemophilia A Market-Mild to Moderate Patients on Prophylaxis Therapy
3.1.10 The US Hemophilia A Market-Mild to Moderate Patients on On-Demand Therapy
3.1.11 The US Hemophilia B Market Forecast by Value
3.1.12 The US Hemophilia B Market- Treated Patients Volume Forecast
3.1.13 The US Hemophilia B Market- Severe Patients on Prophylaxis Therapy
3.1.14 The US Hemophilia B Market- Severe Patients on On-Demand Therapy
3.1.15 The US Hemophilia B Market- Mild to Moderate Patients on Prophylaxis Therapy
3.1.16 The US Hemophilia B Market- Mild to Moderate Patients on On-Demand Therapy
3.2 Europe
3.2.1 Europe’s Hemophilia Market- Patient Volume Forecast
3.2.2 Europe’s Hemophilia A Market- Patient Volume Forecast
3.2.3 Europe’s Hemophilia B Market- Patient Volume Forecast

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increased Focus on Prophylactic Treatment
4.1.2 Increasing Diagnosis Rate
4.1.3 Rising Healthcare Expenditure
4.2 Key Trends & Development
4.2.1 Shifting to Extended Half Life Therapies
4.2.2 Development of Novel Hemophilia Treatments
4.2.3 Popularity of Gene Therapy
4.3 Challenges
4.3.1 High Cost of Treatment
4.3.2 Reluctance to Switch to New Therapies

5. Competitive Landscape
5.1 Global Hemophilia Market
5.1.1 Revenue and Market Cap Comparison
5.2 Global Hemophilia A Market
5.2.1 Global Hemophilia A Market Share by Company
5.2.2 Global Hemophilia A Factor VIII Products Market Share by Company
5.2.3 Global Hemophilia A FVIII Gene Therapy Market Share Forecast
5.3 Global Hemophilia B Market
5.3.1 Global Hemophilia B Market Share by Company
5.3.2 Global Hemophilia B Factor IX Products Market Share Forecast
5.3.3 Global Hemophilia B Factor IX Gene Therapy Market Share Forecast

6. Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Bayer Group
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Shire PLC
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Novo Nordisk
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

List of Charts

  • Types of Hemophilia
  • Global Hemophilia Market by Value (2013-2017)
  • Global Hemophilia Market Forecast by Value (2018-2022)
  • Global Hemophilia Market by Treatment Regimen (2017)
  • Global Hemophilia Market by Type (2017)
  • Global Hemophilia A Market Forecast by Value (2017-2022)
  • Global Hemophilia A Market by Severity (2017)
  • Global Hemophilia A Market by Treatment Regimen (2017/2022)
  • Global Hemophilia with Inhibitors Market Forecast by Value (2017-2022)
  • Global Hemophilia B Market Forecast by Value (2017-2022)
  • Global Hemophilia B Market by Severity (2017)
  • Global Hemophilia B Market by Treatment Regimen (2017/2022)
  • The US Hemophilia Market by Value (2013-2017)
  • The US Hemophilia Market Forecast by Value (2018-2022)
  • The US Hemophilia Market by Type (2017)
  • The US Hemophilia A Market Forecast by Value (2017-2022)
  • The US Hemophilia A Market by Products (2017)
  • The US Hemophilia A Market-Treated Patient Volume Forecast (2017-2022)
  • The US Hemophilia A Market-Severe Patients on Prophylactic Therapy (2017-2022)
  • The US Hemophilia A Market-Severe Patients on On-Demand Therapy (2017-2022)
  • The US Hemophilia A Market-Mild to Moderate Patients on Prophylaxis Therapy (2017-2022)
  • The US Hemophilia A Market-Mild to Moderate Patients on On-Demand Therapy (2017-2022)
  • The US Hemophilia B Market Forecast by Value (2017-2022)
  • The US Hemophilia B Market- Treated Patients Volume Forecast (2017-2022)
  • The US Hemophilia B Market- Severe Patients on Prophylaxis Therapy (2017-2022)
  • The US Hemophilia B Market- Severe Patients on On-Demand Therapy (2017-2022)
  • The US Hemophilia B Market- Mild to Moderate Patients on Prophylaxis Therapy (2017-2022)
  • The US Hemophilia B Market- Mild to Moderate Patients on On-Demand Therapy (2017-2022)
  • Europe’s Hemophilia Market- Patient Volume Forecast (2017-2022)
  • Europe’s Hemophilia A Market- Patient Volume Forecast (2017-2022)
  • Europe’s Hemophilia B Market- Patient Volume Forecast (2017-2022)
  • Market Share of Hemophilia A Patients on Prophylaxis in the US (Q1-2015-Q1-2017)
  • Market Share of Hemophilia B Patients on Prophylaxis in the US (Q1-2015-Q1-2017)
  • Global Identified Hemophilia Patients Volume (2010-2017)
  • Global Healthcare Expenditure (2013-2017)
  • Global Hemophilia A Market Share by Company (2017)
  • Global Hemophilia A Factor VIII Products Market Share by Company (2022/2030)
  • Global Hemophilia A FVIII Gene Therapy Market Share Forecast (2030)
  • Global Hemophilia B Market Share by Company (2017)
  • Global Hemophilia B Factor IX Products Market Share Forecast (2022/2030)
  • Global Hemophilia B Factor IX Gene Therapy Market Share Forecast (2030)
  • Pfizer Inc.'s Revenue Share by Major Business Segment (2017)
  • Pfizer Inc.’s Revenue and Net Income (2013-2017)
  • Pfizer Inc. R&D Expenses (2015-2017)
  • Bayer Group’s Net Sales Share by Business Segments (2016)
  • Bayer Group’s Net Sales and Net Income (2012-2016)
  • Shire PLC’s Revenue Share by Franchise (2017)
  • Shire PLC’s Revenue and Net Income (2013-2017)
  • Novo Nordisk’s Net Sales Share by Business Segments (2017)
  • Novo Nordisk’s Net Sales and Net Profit (2013-2017)

List of Tables

  • Signs & Symptoms of Hemophilia
  • Extended Half Life Products (2017)
  • Development of New Novel Hemophilia Treatments (2017)
  • Hemophilia Gene Therapy Candidates (2017/2018)
  • Revenue & Market Cap Comparison by Key Players (2017)
  • Major Business Segments of the Pfizer Inc. (2017)
  • Major Products Developed by Bayer Group (2017/2018)
  • Shire PLC’s Major Product Approvals & Launches (2017)
  • Novo Nordisk’s Research and Development (2015-2017)
  • Novo Nordisk’s Product Pipeline (2017)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bayer Group
  • Novo Nordisk
  • Pfizer Inc.
  • Shire PLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll